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Background: Carbonic anhydrase IX (CA IX) is a transmembrane enzyme that is present in many types of solid
tumors. Expression of CA IX is driven predominantly by the hypoxia-inducible factor (HIF) pathway and helps
to maintain intracellular pH homeostasis under hypoxic conditions, resulting in acidification of the tumor
microenvironment. Carnosine (β-alanyl-L-histidine) is an anti-tumorigenic agent that inhibits the proliferation of
cancer cells. In this study, we investigated the role of CA IX in carnosine-mediated antitumor activity and whether
the underlying mechanism involves transcriptional and translational modulation of HIF-1α and CA IX and/or
altered CA IX function.
Methods: The effect of carnosine was studied using two-dimensional cell monolayers of several cell lines with
endogenous CA IX expression as well as Madin Darby canine kidney transfectants, three-dimensional HeLa
spheroids, and an in vivo model of HeLa xenografts in nude mice. mRNA and protein expression and protein
localization were analyzed by real-time PCR, western blot analysis, and immunofluorescence staining, respectively.
Cell viability was measured by a flow cytometric assay. Expression of HIF-1α and CA IX in tumors was assessed by
immunohistochemical staining. Real-time measurement of pH was performed using a sensor dish reader. Binding
of CA IX to specific antibodies and metabolon partners was investigated by competitive ELISA and proximity
ligation assays, respectively.
Results: Carnosine increased the expression levels of HIF-1α and HIF targets and increased the extracellular pH,
suggesting an inhibitory effect on CA IX-mediated acidosis. Moreover, carnosine significantly inhibited the growth
of three-dimensional spheroids and tumor xenografts compared with untreated controls. Competitive ELISA showed
that carnosine disrupted binding between CA IX and antibodies specific for its catalytic domain. This finding was
supported by reduced formation of the functional metabolon of CA IX and anion exchanger 2 in the presence of
carnosine.
Conclusions: Our results indicate that interaction of carnosine with CA IX leads to conformational changes of
CA IX and impaired formation of its metabolon, which in turn disrupts CA IX function. These findings suggest
that carnosine could be a promising anticancer drug through its ability to attenuate the activity of CA IX.
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Hypoxia in the tumor microenvironment is associated with
poor prognosis and a poor response to therapy, underlying
the importance of studying the effect of potential anti-
cancer drugs on the hypoxia pathway. Stabilization of
hypoxia-inducible factor 1 (HIF-1) as an adaptive response
to hypoxic conditions in tissues results in transcriptional
activation of many genes that play an important role in
cancer-related processes, such as angiogenesis, cell sur-
vival, glucose metabolism, and cell invasion. HIF-1 is a
heterodimer consisting of a constitutively expressed HIF-
1β subunit and a HIF-1α subunit that is regulated through
O2-dependent degradation modulated by prolyl hydroxyl-
ation. The von Hippel–Lindau (VHL) tumor-suppressor
protein binds specifically to hydroxylated HIF-1α which is
then ubiquitylated by E3 ubiquitin-protein ligases and
rapidly degraded by the proteasome [1].
The dipeptide β-alanyl-L-histidine, also known as
carnosine, was described for the first time in the 19th
century [2]. Carnosine is naturally present in cardiac and
skeletal muscles and the central nervous system, and is
synthesized from β-alanine and L-histidine by carnosine
synthase in muscle cells, glial cells, and oligodendrocytes
[3]. Carnosine plays a role as a physiologic pH buffering
substance and antioxidant [4]. It induces variable effects
on the cardiovascular system, including down-regulation
of blood pressure [5,6], inhibition of glycosylated low-
density lipoprotein formation [7], and inhibition of angio-
tensin-converting enzyme activity [8]. It also acts as an
anti-aging agent [9]. Moreover, it inhibits proliferation of
cells derived from patients with glioblastoma [10] and the
growth of tumors formed from neoplastic cell lines, such
as Sarcoma-180 tumor cells [11], various neoplastic hu-
man and rodent cell lines [12], cells expressing the human
epidermal growth factor receptor 2 (Her2/neu) [13], and
HCT116 colon cancer cells [14]. Conversely, carnosine
enhances the proliferation potential of cultured normal
human fibroblasts, lengthens their lifespan, and suppresses
senescence [9]. The mechanism of its action in tumor cells
remains unclear.
Proteomic studies of glioblastoma cells after treat-
ment with carnosine revealed significantly reduced ex-
pression of von Hippel-Lindau binding protein 1 (VBP1)
[15], a protein that binds to the von Hippel-Lindau pro-
tein [16] and thus is linked to HIF-1α signaling. Pretreat-
ment with carnosine reduced the induction of HIF-1α
protein in H9c2 cardiomyoblasts during hypoxia and
further reduced its already low level under normoxia; the
level of HIF-1 mRNA was transiently reduced after car-
nosine treatment, but increased after 24 h in a similar
manner to controls. A similar experiment with human
astrocytes showed that carnosine did not significantly
alter the pattern of HIF-1α protein expression in these
cells [17].Carbonic anhydrase IX (CA IX) is a membrane-bound
metalloenzyme that is expressed in a broad range of
solid tumors [18]. The main function of CA IX is to
maintain intracellular pH homeostasis under hypoxic
conditions that are common in solid tumors although it
also modulates E-cadherin-mediated cell adhesion via its
interaction with beta-catenin, which could be of poten-
tial significance in hypoxia-induced tumor progression
[19]. CA IX contributes to ion transport and pH control
by forming a bicarbonate transport metabolon with the
sodium bicarbonate transporter NBCe1 and anion ex-
changer 2 (AE2) [20,21]. CA IX expression in tumors is
recognized as a marker of hypoxia and an indicator of
poor prognosis. Moreover, CA IX possesses clinical po-
tential as a target for anticancer treatment [22]; indeed,
functional inhibition of CA IX has been proposed as an
attractive option for therapeutic targeting of various
hypoxic tumors [18]. Transcription of the gene encoding
CA IX is primarily activated by the hypoxia-inducible
HIF-1 transcription factor that binds to the hypoxia re-
sponse element (HRE) located next to the transcription
initiation site [23]. Phosphorylation of Thr443 of CA IX
by protein kinase A (PKA) in hypoxic cells is critical for
its activation [21].
Because kinetic and X-ray crystallographic studies sug-
gest that carnosine is a potent activator of the carbonic
anhydrase isoforms hCA I, II, and IV [24] and the studies
described above indicate that carnosine affects the HIF-1
signaling pathway, we initially examined whether CA IX is
involved in the antitumor activity of carnosine. We subse-
quently investigated whether carnosine exerts its effect on
CA IX through modulation of transcription and transla-
tion levels of HIF-1α and CA IX and/or through altering
CA IX function.
Methods
Cell culture and spheroid preparation
Madin-Darby canine kidney (MDCK), HeLa, HT-29, and
SiHa cell lines were obtained from the American Type
Culture Collection and cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal calf
serum (FCS; Bio Whittaker) and gentamicin (Sandoz)
at 37°C and 5% CO2 in humidified air. The cells were
counted, seeded in 3- or 6-cm Petri dishes (Greiner)
for 24 h, and treated with L-carnosine (Sigma Aldrich)
under normoxic (incubator, 5% CO2) and hypoxic (2% O2,
2% H2, 5%CO2, 91% N2, anaerobic workstation, Ruskinn
Technology) conditions.
HeLa spheroids were generated by seeding cells (1,250
cells/well) in 96-well plates (Greiner) coated with 1%
agarose. After 4 days of incubation at 37°C and 5% CO2,
the spheroids were photographed and treatment was
initiated by addition of fresh medium with or without
carnosine. In all experiments, at least 30 replicate wells
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groups. Photographs were taken every 48 h. At the end
of the experiment, extracellular pH was measured and
the spheroids were subjected to flow cytometric analysis
to determine cell viability.
Measurement of extracellular pH using sensor dish reader
The sensor dish reader (SDR; PreSense) monitors pH in
real-time in special plates (HydroDish®) using a non-
invasive technique that detects the luminescence lifetime
of a sensor spot at the bottom of each well that is
dependent on the pH of the surrounding sample. Cells
were seeded into wells and allowed to attach. Measure-
ment was started on the second day, when the cells
reached 80% confluence. Cells were cultured in the pres-
ence or absence of carnosine under hypoxic or normoxic
conditions as described above. The pH was measured by
the SDR every 30 min.
Competitive ELISA
HeLa cells were cultured in 96-well plates for 24 h in
normoxic conditions and then in hypoxic conditions for
additional 24 h, followed by 6-h treatment with different
concentrations of carnosine (1.531, 3.0625, 6.125, 12.25,
25, 50, 100 mM) with or without specific antibodies
against different domains of the CA IX protein (MAb10,
MAb12) [25]. Cells were fixed with methanol, blocked
with 10% FCS in phosphate-buffered saline (PBS) for
30 min, and incubated with HRP-conjugated secondary
antibody for 1.5 h at room temperature. Absorbance and
color changes were measured at 492 nm.
Immunofluorescence (IF)
HeLa cells grown on glass coverslips were fixed in
methanol. After blocking in 3% bovine serum albumin
(BSA)/PBS, the cells were incubated with primary anti-
bodies against CA IX (M75 hybridoma medium) or
against HIF-1α (diluted in PBS with 0.5% BSA) for 1 h at
37°C. The cells were washed four times for 10 min with
PBS containing 0.02% Tween 20, incubated for 1 h at
37°C with Alexa-conjugated secondary antibody diluted
in PBS with 0.5% BSA, and washed three times with
PBS. All experiments were also performed in the absence
of the primary, secondary, or both antibodies as negative
controls. Nuclei were stained with 4',6-diamidino-2-phe-
nylindole (DAPI; 1:36000; Sigma Aldrich) for 5 min. Fi-
nally, the cells were mounted in Fluoroshield Mounting
Medium (Abcam) and analyzed by laser scanning micros-
copy (LSM 510 Meta Microscope; Zeiss).
To investigate the influence of carnosine treatment on
the binding of fluorescein isothiocyanate (FITC)-labeled
CA specific inhibitor (FITC_CAI), HeLa cells were cul-
tured without and with 20 mM carnosine in normoxic and
hypoxic conditions. After 48 h, the medium was replacedby fresh medium containing FITC_CAI at a final con-
centration of 0.1 mmol/L. After further incubation for 1 h,
the live cells were analyzed by laser scanning microscopy
(LSM 510 Meta Microscope; Zeiss) using the incubation
stage set at 37°C and 5% CO2. FITC-labeled carbonic anhy-
drase specific inhibitor (FITC_CAI) [26] was a gift from
Professor C.T. Supuran.
Proximity ligation assay
The proximity ligation assay (PLA) was used for in situ
detection of the interaction between CA IX and AE2. The
assay was performed in a humid chamber at 37°C accord-
ing to the manufacturer’s instructions (Olink Bioscience).
SiHa cells were seeded on glass coverslips and allowed to
attach before transfer to 2% hypoxia and further cultured
for 24 h. After starvation overnight in DMEM supple-
mented with 0.5% FCS, carnosine was added to selected
samples (final concentration 20 mM) and the control and
treated cells were cultured for an additional 24 h in hyp-
oxia. The cells were fixed with methanol, blocked with 3%
BSA/PBS for 30 min, incubated with a mixture of anti-
bodies against CA IX and AE2 for 1 h, washed three
times, and incubated with plus and minus PLA probes for
1 h. The cells were washed, incubated with ligation mixture
containing connector oligonucleotides for 30 min, washed
again, and incubated with amplification mixture containing
fluorescently labeled DNA probe for 100 min. After a final
wash, the samples were mounted and the signal repre-
senting interaction between CA IX and AE2 was analyzed
using a Zeiss LSM 510 Meta confocal microscope.
Flow cytometry analysis (FACS)
HeLa cells were treated with carnosine (5–40 mM) under
normoxic and hypoxic conditions. After 48 h, the cells
were detached using trypsin, which was then inactivated
by 10% FCS in PBS with 2 mM EDTA. Cells were cen-
trifuged and resuspended in PBS with 10% FCS at a final
concentration of 1 × 106 cells/mL. For measurement of
the surface expression of CA IX protein, 100 μL of hybrid-
oma medium containing a M75 antibody against CA IX
was added to 100 μL of the sample. After incubation at 4°
C for 30 min, the cells were centrifuged, washed twice
with PBS, and incubated with the secondary Alexa Fluor
488 donkey anti-mouse antibody. Cells stained with only
secondary antibody were used as a negative control. For
assessment of cell viability, the cells were stained with
propidium iodide at a final concentration of 5 μg/mL and
incubated for 5 min at room temperature. The samples
were analyzed using a Guava EasyCyte Plus flow cyto-
meter with Guava Express Pro 2.2.3 software (Millipore).
Western blotting
For western blotting (WB), cells grown in confluent
monolayers were rinsed twice with cold PBS, resuspended
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pH 7,5; 150 mM NaCl; 0,5% Nonidet P-40) containing
protease (Roche) and phosphatase inhibitors cocktail
(Sigma Aldrich), disrupted by sonication and cleared by
centrifugation. Protein concentrations were quantified
using the BCA protein assay reagents (Pierce). Protein ex-
tracts (100 μg/lane) were resolved in 8% SDS-PAGE and
transferred to a polyvinylidene difluoride (PVDF) mem-
brane (Macherey-Nagel). The total level of CA IX protein
was detected by HRP-conjugated M75 antibody, and
HIF-1α and actin were detected using purified primary
antibodies and the appropriate HRP-conjugated secondary
antibodies as described in the section Antibodies. Protein
bands were visualized using an enhanced chemilumines-
cence kit (GE Healthcare Bio-Sciences).
Real-Time quantitative PCR (qPCR)
HeLa cells were cultured with or without 20 mM carnosine
in normoxia and hypoxia for 48 h. Total RNA was isolated
using Instapure solution (Eurogentech) and reverse tran-
scription of RNA was performed with the High-Capacity
cDNA Reverse Transcription kit (Applied Biosystems) ac-
cording to the manufacturer’s recommendations. Amplifi-
cation was performed in a Stratagene Mx 3005P thermal
cycling block (Agilent Technologies). PCR was carried out
in 20-μL volumes using Maxima Syber Green PCR Master
Mix (Fermentas) for 10 min at 95°C for initial denatur-
ation followed by 40 cycles of 95°C for 15 s and 60°C for
1 min. Sample Ct values were normalized to actin. Relative
expression was calculated using the ΔΔCt method. All
amplifications were performed in triplicate in three inde-
pendent experiments. Oligonucleotides used for real-time
qPCR were as follows: HIF-1α sense 5′-GCTTGGTGCTG
ATTTGTGAACC-3′, HIF-1α antisense 5′-GCATCCTG
TACTGTCCTGTGGTG-3′, Actin sense 5′-CCAACCGC
GAGAAGATGACC-3′, Actin antisense 5′-GATCTTCAT
GAGGTAGTCAGT-3′, GLUT-1 sense 5′-CTCCTTTCTC
CAGCCAGCAATG-3′, GLUT-1 antisense 5′-CCAGCAG
AACGGGTGGCCATAG-3′, VEGF sense 5′-CAGCACG
GT CCCTCTTGGAA-3′, VEGF antisense 5′-CCTCCTC
TTCCCTGTCAGGA-3′, VBP1 sense 5′-CTGTGGTTGG
GGGCTAATGT-3′, VBP1 antisense 5′-CCCTGGCCATA
TTGACTTCTGT-3′.
Chromatin immunoprecipitation (ChIP)
HeLa cells were plated onto 10-cm Petri dishes, cultured
to approximately 70% monolayer density, and then incu-
bated in the presence or absence of 20 mM carnosine in
hypoxic conditions for additional 48 h. The cells were
fixed in 1% formaldehyde directly in medium at room
temperature (~21°C) for 15 min. Chromatin isolation
and immunoprecipitation with antibody against HIF-1α
were performed using Exacta ChIP (R&D Systems) accor-
ding to the manufacturer’s instructions. DNA was purifiedusing the Wizard SV Gel and PCR Clean-Up System
(Promega). Amplification of the samples was performed
with HF Phusion polymerase (Thermo Fisher) in an
automatic DNA thermal cycler (Eppendorf) using initial
denaturation at 98°C for 9 min followed by 43 cycles of
denaturation at 97°C for 1 min and annealing at 62°C for
1 min. Primers flanking the HRE elements within the CA9
and VEGF promoter were as follows: hCA9 HRE sense 5′-
TCCTAGCTTTGGTATGGGGGAGAG-3′, hCA9 HRE
antisense 5′-AGTGACAGCAGCAGTTGCACAGT-3′,
hVEGF HRE sense 5′-CCTCAGTTCCCTGGCAACAT
CTG-3′, hVEGF HRE antisense 5′-CCTCAGTTCCCT
GGCAACATCTG-3′.
Animal experiments
CD1 nude mice were purchased from Charles River
Laboratories. The animals had access to standard food
and water ad libitum. Ten male animals were injected
subcutaneously into the flank on both sides with 2 × 106
HeLa cells in 100 μL sterile PBS. At 14 days after im-
plantation, the animals were divided into two groups:
the first group (five animals) was treated with carnosine
(50 μL of 1 M stock, dissolved in sterile PBS) adminis-
tered subcutaneously 2 cm from the implantation site
every second day, and the second group (five animals)
was used as a control (sterile PBS only). Tumor size was
determined by caliper measurements and was calculated
according to the formula W2 *L/2, where W is the width
and L the length of the tumor. All animal protocols were
approved by the Institutional Ethics Committee of the
Institute of Virology and the State Veterinary and Food
Institute of the Slovak Republic (Permit no. 4245/13-221).
Immunohistochemistry (IHC)
Tumor specimens were fixed in formalin, dehydrated in
an ethanol series, treated with xylene, and mounted in
paraffin. Serial sections of tissues were cut and deparaffi-
nized in a xylene and ethanol series. Immunostaining for
HIF-1α was performed after antigen retrieval (125°C for
5 min, 95°C for 10 min in citrate buffer, pH 6) using the
Dako Cytomation Catalyzed Signal Amplification System
kit (Dako). CA IX staining was performed using Dako
EnVision + System-HRP (Dako). Cell nuclei were counter-
stained with hematoxylin solution.
Antibodies
Primary antibodies: mouse monoclonal anti-human HIF-
1α (dilutions used: WB 1:250, IF 1:150, IHC 1:150; BD
Transduction Laboratories); goat polyclonal anti-human
actin (WB 1:1000; Santa Cruz Biotechnology); rabbit anti-
human AE2 (PLA 1:500) [20]; mouse monoclonal anti-
human carbonic anhydrase IX-M75 hybridoma medium
(PLA, FACS, IF non-diluted; IHC 1:100); purified mouse
monoclonal anti-human carbonic anhydrase IX–MAb10,
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against CA IX conjugated with HRP (WB 1:7500).
Secondary antibodies: Alexa Fluor 488-conjugated don-
key anti-mouse IgG (IF 1:1000, FACS 1:3000; Invitrogen);
HRP-conjugated goat anti-mouse IgG (WB 1:5000; Dako);
HRP-conjugated rabbit anti-goat IgG (WB 1:5000; Dako).
Results
Carnosine reduces CAIX-mediated acidification
Cultivation of HeLa cells under hypoxia for 48 h in the
presence of carnosine (5–40 mM) resulted in reduced
acidification of the extracellular environment in a dose-
dependent manner (Figure 1A). The effect of carnosine
on HeLa cells in normoxic conditions was substantially
smaller (data not shown). Because of its physiologic
relevance, a carnosine concentration of 20 mM was
selected for further tests on different cancer cell lines
(SiHa, HeLa, HT-29). Incubation with carnosine markedly
reduced the acidification of growth media in hypoxicFigure 1 Carnosine decreases acidification of the growth media of dif
conditions in the presence of different concentrations of carnosine (5–40 m
Carnosine treatment markedly decreased the acidification of growth media
between samples treated with different carnosine concentrations and the u
cells were exposed to hypoxia for 48 h in the presence of 20 mM carnosin
values of carnosine-treated cells and their respective untreated controls. Ca
cell lines, except for MDCK mock cells in which the effect of carnosine was
untreated control and carnosine-treated cells were evaluated by a t-test (*pconditions for all cell lines studied (Figure 1B, Additional
file 1). We also observed a carnosine-mediated decrease in
acidification in MDCK cells transfected with CA IX,
whereas the effect of carnosine on their mock-transfected
counterparts was considerably smaller.
Effect of carnosine on the level of total CA IX
To determine whether the carnosine-mediated reduction
in extracellular acidification of CA IX-positive cells is
related to CA IX protein level, we cultivated HeLa cells
in hypoxic conditions and used our in-house anti-CA IX
antibody M75 to measure CA IX protein levels. The
level of CA IX protein increased after carnosine treat-
ment (Figure 2A). This result was confirmed by immu-
nofluorescent staining of CA IX (Figure 2B) and by flow
cytometry analysis, which showed that 20 mM carnosine
treatment increased the levels of surface CA IX in HeLa
cells under hypoxia (Figure 2C). Carnosine did not change
the degree of phosphorylation at Thr443, suggesting thatferent cell lines. (A) HeLa cells were incubated for 48 h in hypoxic
M) and the extracellular pH was measured by SDR in real time.
in a dose-dependent manner. **denotes p < 0.01 for the comparison
ntreated control. (B) SiHa, HeLa, HT-29, MDCK-CA IX, and MDCK-mock
e. The columns in the graph represent differences in the endpoint pH
rnosine caused considerable alkalization of growth media in all studied
noticeably lower. Differences between endpoint pH values of the
< 0.05, **p < 0.01).
Figure 2 Effect of carnosine on the level of CA IX protein. HeLa
cells were cultured in hypoxic conditions for 48 h in the presence of
20 mM carnosine. Carnosine induced a slight increase in CA IX
protein level in hypoxic cells as shown by western blot analysis (A)
and immunofluorescence (scale bar 20 μm) (B). This result was
confirmed by flow cytometric analysis using M75 antibody against
CA IX (C). After treatment with 20 mM carnosine, the level of
membrane-localized CA IX increased by 48% compared with the
control. Other concentrations of carnosine did not have a comparable
effect on CA IX protein level. Differences between the untreated control
and carnosine-treated samples were evaluated by a t-test (*p < 0.05).
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ylation by PKA (Additional file 2).
Carnosine treatment increases the level of HIF-1α protein
and mRNA and the expression of hypoxia-regulated genes
Because transcription of CA IX is activated by HIF-1α,
we tested whether carnosine influenced HIF-1α protein
and mRNA levels in HeLa cells. HeLa cells were cul-
tured in hypoxic conditions for 48 h with or without
20 mM carnosine. Western blot analysis showed a signifi-
cant increase in HIF-1α signal in cells treated with carno-
sine compared with controls (Figure 3A). This finding was
supported by immunofluorescent staining of HIF-1α,
which showed a stronger HIF-1α signal in the nuclei of
treated cells (Figure 3B). Data from qPCR analysis con-
firmed an increased level of HIF-1α mRNA after carnosine
treatment under hypoxia compared with the untreated
control (Figure 3C). The activity of HIF-1α was demon-
strated by the increase in mRNA expression of the HIF-1α
targets vascular endothelial growth factor (VEGF) and glu-
cose transporter 1 (GLUT-1) after carnosine treatment in
hypoxia (Figure 3C). Moreover, ChIP analysis showed a
moderate increase in binding of HIF-1α to the HRE in
both CA9 and VEGF promoters (Figure 3D). Interestingly,
the level of VBP1 mRNA decreased after carnosine treat-
ment compared with the control (Figure 3C), indicating
reduced degradation and increased stabilization of HIF-1α
protein.
Carnosine inhibits binding of CA-specific inhibitor and CA
IX-specific antibodies and impairs formation of the CA IX
metabolon
We next investigated binding of fluorescein-conjugated
CA-specific homosulfanilamide inhibitor (FITC_CAI) to
carnosine-treated and untreated cells in hypoxic condi-
tions. Svastova et al. previously showed that FITC_CAI
binds only to hypoxic cells expressing CA IX, and it is
widely accepted that this inhibitor binds only to catalyt-
ically active CA IX that has been activated by hypoxia
[26]. We observed a reduction in the immunofluorescent
signal of FITC-CAI after carnosine treatment of HeLa
cells (Figure 4A) and MDCK-CA IX cells (data not
shown) under hypoxia, indicating a decrease in CA IX
activity in the presence of carnosine. This assumption is
supported by the results of competitive inhibition ELISA
performed in HeLa cells after culture in the presence of
different concentrations of carnosine together with the
CA IX-specific antibodies MAb10 and MAb12 directed
against conformational epitopes in the catalytic domain
of CA IX. As shown in Figure 4B, carnosine inhibited
the binding of MAb10 and MAb12. Furthermore, a pro-
ximity ligation assay showed that carnosine treatment
reduced the signal arising from direct interaction of CA
IX and AE2 in the metabolon of SiHa cells (Figure 4C).
Figure 3 Effect of carnosine on the level of HIF-1α. HIF-1α protein level was increased in hypoxic HeLa cells cultured in the presence of
20 mM carnosine for 48 h as demonstrated by western blot (A) and immunofluorescence (scale bar, 10 μm) (B). (C) Carnosine treatment increased
expression of HIF-1α mRNA and its target genes VEGF and GLUT-1 under hypoxic conditions. Concurrently, the mRNA level of VBP1, a protein that binds
to VHL and is involved in HIF-1α degradation, was decreased. (D) Chromatin immunoprecipitation assay performed under the same conditions
demonstrated that HIF-1α bound to hypoxia-responsive elements in the promoter region of VEGF and CA9 genes.
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viability
To confirm the effect of carnosine in a physiologically
more relevant three-dimensional (3D) environment, we
treated spheroids formed by HeLa cells with carnosine
added to the culture medium only after the spheroids
had already formed, or with carnosine present during
the period of spheroid formation. Both experimental
groups formed spheroids, indicating that spheroid for-
mation was not significantly affected by carnosine. At
the end of the experiment the carnosine-treated spher-
oids in both groups had a significantly smaller (almost
50% smaller) diameter than the controls; moreover, the
extracellular pH of the treated groups was higher in the
treated cultures than in the controls (Figure 5A, 5B).
Data from flow cytometric analysis showed that car-
nosine treatment of a two-dimensional monolayer culture
decreased the viability of hypoxic cells in a dose-dependent
manner: 5 mM carnosine decreased HeLa cells viability
only slightly, 10 mM carnosine by approximately 10%, and
20 mM by approximately 15% (Figure 5C). In comparison,
the viability of HeLa cells in normoxic conditions remainedrelatively constant in the presence of different concentra-
tions of carnosine (data not shown). In 3D culture, where
hypoxia develops in the center of spheroids, we observed a
marked decrease in viability of HeLa spheroids of 50% after
treatment with 20 mM carnosine compared with the
controls (Figure 5D).
Carnosine reduces tumor size in an experimental mouse
xenograft model
Tumor growth was visible 7 days after subcutaneous
implantation of HeLa cells in all animals. On the 14th day
of the experiment, we separated the mice into two groups
and started subcutaneous administration of carnosine
solution to animals in the carnosine group. At the same
time, we commenced caliper measurement of the tumors.
All animals had comparable-sized tumors at the start of
carnosine treatment. Between the 21st and 28th day of
the experiment we noticed faster growth of tumors in
the control group compared with the carnosine-treated
group, in which the average tumor size remained relatively
constant. Although several tumors continued to grow in
the carnosine-treated group, the rate of tumor growth was
Figure 4 Carnosine impairs binding of CA IX-specific inhibitor and antibodies and affects formation of a CA IX metabolon.
(A) Immunofluorescence signal of FITC-labeled CA specific inhibitor, which binds only to hypoxic cells with catalytically active CA IX, was markedly
reduced after treatment of HeLa cells with 20 mM carnosine in hypoxia for 48 h. (B) Graph of competitive inhibition ELISA showing the percentage of
inhibition after cultivation of HeLa cells with different concentrations of carnosine together with specific CA IX antibodies MAb10 and MAb12. Binding
of antibodies to conformational epitopes in the catalytic domain of CA IX was inhibited by carnosine in a concentration-dependent manner. (C) SiHa
cells cultured in islands under hypoxic conditions were analyzed by proximity ligation assay to visualize direct interaction between CA IX and the
anion exchanger AE2 in the functional metabolon. The positive signal represented by bright white dots was considerably reduced in cells treated
with 20 mM carnosine for 24 h, supporting the proposal that binding of carnosine alters the conformation of CA IX. Scale bar, 20 μm.
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and several tumors even became smaller (Figure 6A).
These observations were confirmed after the final exa-
mination, when we found a significant difference in the
weight of tumors between the control and carnosine-
treated groups (Figure 6B). Immunohistochemical staining
of formalin-fixed, paraffin-embedded tumor tissues dem-
onstrated enhanced intensity of HIF1-α and CA IX staining
in the carnosine-treated group (Figure 6C). These results
correspond with the higher level of both proteins observed
in vitro.
Discussion
Identification of a potent anticancer drug that does not
have adverse side effects remains a highly topical issue.
The clinical use of carnosine in children with autism [27]
and the use of a zinc complex of L-carnosine (Polaprezinc)as an anti-ulcer drug in Japan since 1994 have yielded
encouraging results [28]. Application of this dipeptide in
anti-cancer therapy is still an emerging field, but carnosine
seems to be a promising candidate because of its anti-
tumorigenic effects combined with its natural presence in
the body and its beneficial influence on normal cells.
These positive effects include protection of astroglial cells
by NO trapping [29], protection against hypoxia-ischemia
brain damage [30], reduction in the development of
inflammation and tissue injury associated with spinal cord
trauma [31], protection of lung tissue against bleomycin-
induced injury [32], prevention of vascular damage in
experimental diabetic retinopathy [33], and protection
against ionizing radiation [34,35].
There is a lack of published data on carnosine admin-
istration in human participants in the setting of cancer
treatment. Two recently published articles report no
Figure 5 Effect of carnosine on spheroid size and cell viability. (A) Images of spheroids cultured in the presence and absence of 20 mM
carnosine. Carnosine was added after spheroids had already formed (upper image) or before spheroid formation (lower image). The images show
the same time points of spheroid growth, although the duration of carnosine treatment differs as indicated, depending whether carnosine was
added before or after spheroid formation. pH values represent measured pH of media collected from all respective spheroid samples (N > 30) at
the end of the experiment. (B) In both experimental conditions, the diameters of carnosine-treated spheroids were significantly smaller than those
of controls (t-test, **p < 0.01). (C) Flow cytometry showed that treatment with different concentrations of carnosine (5–40 mM) decreased cell
viability in hypoxic conditions in a dose-dependent manner (t-test, *p < 0.05, **p < 0.01). Numbers in the columns give the ratio for the viability of
a carnosine-treated sample and the respective hypoxic control (set as 100%). The ratio of the viability of hypoxic and normoxic controls was 96%.
(D) Cultivation of HeLa spheroids in the presence of 20 mM carnosine significantly reduced cell viability by approximately 50% compared with
the control group (t-test, **p < 0.01).
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dose [36] or 400 mg twice daily [27]. These data indicate
the feasibility of carnosine as a therapeutic agent, although
more clinical trials are clearly needed. In this article, we
focused on the effect of carnosine on the hypoxic pathway,
which is often up-regulated in tumors, and specifically on
its effect on CA IX, expression of which is often associated
with solid hypoxic tumors. The major function of CA
IX in cancer is maintenance of pH homeostasis, which is
related to the acidification of the tumor microenviron-
ment that promotes cancer cell migration and invasive-
ness. Our results showed that carnosine causes a shift in
extracellular pH (pHe) from acidic to alkaline for vari-
ous cancer cell lines (HeLa, SiHa, HT-29) under hypoxic
conditions. Although carnosine functions as a physio-
logic buffer, the observed change in pHe cannot be attri-
buted to its buffering capacity alone. pH measurements
of mock-transfected and CA IX-transfected MDCKcells demonstrated that carnosine treatment leads to a
reduction of CA IX acidification activity, indicating a
direct influence of carnosine on CA IX function.
Transcription of CA9 is induced by the binding of
HIF-1α to its core promoter [23]. Available information
on the effect of carnosine on HIF-1α is very limited.
Using a gene reporter assay, Oppermann et al. found en-
hanced activity of HIF-1α in the presence of carnosine and
hypoxic conditions in the glioblastoma cell lines T98G,
LN405, and 1321N1 and in one primary culture [37]. In
contrast, Bharadwaj et al. showed that carnosine treatment
decreased HIF-1α expression in H9c2 cardiomyoblasts, but
not in human astrocytes; however, neither of these cell
lines is cancerous [17]. In our study, carnosine treatment
increased protein and mRNA levels of HIF-1α, and its ef-
fect on HIF-1α activity was demonstrated by up-regulation
of the target genes CA9, VEGF, and GLUT1 through the
HRE element in their promoters. Degradation of HIF-1α
Figure 6 Effect of carnosine in a mouse xenograft model.
(A) Graph showing slower growth of tumors in the group treated
with carnosine. Carnosine treatment began on the 14th day after
subcutaneous implantation of HeLa cells, and tumor size was
measured using a caliper during treatment. (B) There was a
significant difference in the weight of tumors from treated and
control groups (t-test, **p < 0.01). (C) Immunohistochemical staining
of tumor tissue sections demonstrated enhanced expression of
HIF-1α and CA IX proteins in the carnosine-treated group.
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which interacts with von Hippel-Lindau binding protein 1
(VBP1) and forms a complex that is transported to the
nucleus or cytoplasm. Proteomic studies of glioblastoma
cells treated with carnosine showed significantly reducedexpression of VBP1 protein and mRNA [15]. This is con-
sistent with our findings that the level of VBP1 mRNA
decreased in hypoxic HeLa cell monolayers after treatment
with carnosine. Hence, the increase in HIF-1α protein level
after carnosine treatment could be a consequence of its
stabilization due to reduced VHL-mediated degradation.
Hypoxia plays an important role in cancer progression
and metastasis [38,39] and there is growing evidence
that altered tumor metabolism and HIF-1-regulated en-
zymes such as CA IX and CA XII may be vital in the
process of primary tumor progression to metastasis.
Tumor-specific expression of CA IX and its association
with tumor invasiveness and poor treatment outcome
has led to interest in targeting this enzyme for cancer
therapy [22,40]. CA IX activity plays an important role in
the survival of tumor cells in hypoxic regions of solid tu-
mors through the neutralization of intracellular pH and
consequential acidification of the extracellular environ-
ment [26]. Because increased expression of HIF-1α and
CA IX in various tumors is believed to be associated with
poor prognosis of cancer patients, an understanding of
their involvement in the induction of tumor cell prolifera-
tion and consequent tumor growth has clinical relevance.
Carnosine inhibits the growth of tumors formed from
different neoplastic cell lines [11-14]. Consistent with
these findings, we observed an approximately 50% de-
crease in the size of carnosine-treated HeLa spheroids and
reduced growth of tumors in carnosine-treated animals.
Our data from immunoblotting, flow cytometry, and
immunofluorescence analyses showed a slight increase
in CA IX protein level after carnosine treatment in
accordance with the increase in HIF-1α, suggesting that
the anti-tumor effect of carnosine cannot be explained by
modulation of the amount of CA IX. Flow cytometric ana-
lysis showed that carnosine markedly reduced the viability
of cells in hypoxic monolayers as well as in a 3D cellular
model in which hypoxia naturally develops. The impaired
viability of carnosine-treated cells is at least partially
attributable to the effect of carnosine on CA IX catalytic
activity and its implications for extracellular pH.
In conditions of hypoxia, and the consequent acidosis
linked to high production of lactic acid, accurate regu-
lation of intracellular pH (pHi) could represent a key
process that allows a cell to escape damage induced by
these unfavorable conditions. Importantly, a change in pHi
of approximately 0.1 units could induce specific effects in
several processes crucial for cell homeostasis, such as ATP
production, cell proliferation, and protein synthesis.
Adaptation of tumor cells to hypoxia is a complex
process involving many metabolic and regulatory path-
ways. The different effect of carnosine on normal and
tumor cells might be associated with metabolic differences
between these cells. Normal cells derive the maximum
possible energy from glucose by oxidizing it completely to
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not available they use anaerobic glycolysis to form lactate
as the end product (2 moles ATP). In contrast, tumor cells
preferentially use the anaerobic pathway. It is possible that
carnosine inhibits glycolytic metabolism prior to the for-
mation of triose phosphate by stimulating the activity of
fructose 1,6-biphosphate, thus creating a fruitless ATP-
consuming cycle [13,41]. In support of this, the amount of
ATP in a HeLa cell monolayer was markedly reduced after
carnosine treatment in hypoxia (data not shown), and a
similar mode of action was observed in studies on differ-
ent cancer cell lines [14,42]. This depletion of ATP could
result in reduced cell proliferation.
The fact that carnosine treatment resulted in a decreased
ability of CA IX-expressing cells to acidify their extra-
cellular environment indicates that carnosine affects CA
IX catalytic function. This is supported by reduced binding
of the homosulfanilamide CA inhibitor (CAI) to carnosine-
treated cells. Fluorescein-conjugated CAI could bind only
to hypoxic cells that expressed CA IX, evoking the idea
that hypoxia induces catalytic activity of CA IX by modu-
lating CA IX folding in a manner that opens the ac-
tive site and makes it accessible to the inhibitor [26].
Other studies showing that binding of the inhibitor was
markedly reduced after reoxygenation of cells also indicate
that sulfonamide-based inhibitors accumulate on CA
IX-positive cells only under hypoxic conditions [43].
Our results further support an interaction between carno-
sine and CA IX protein. The specific antibodies MAb10
and MAb12 used in this study react with conformational
epitopes in the catalytic domain [25]. The results of com-
petitive ELISA indicated that direct binding of carnosine
to CA IX influenced CA IX conformation and reduced
binding of these specific antibodies. A change in CA IX
conformation might also affect interactions of CA IX with
its protein partners in a metabolon and thus modulate CA
IX activity. Indeed, impaired formation of a bicarbonate
transport metabolon was demonstrated by a reduced signal
in the proximity ligation assay between CA IX and AE2.
Although the application of carnosine in clinical
settings, especially as an anti-neoplastic therapeutic,
has been discussed for several years, experimental-based
explanations of its effects are still insufficient and no
double-blind clinical trials have been performed [44].
Nagai and Suda first described the anti-neoplastic effects
of carnosine on Sarcoma-180 cells implanted subcutane-
ously into ddY mice [45]. Renner et al. showed that carno-
sine delays aggressive tumor growth in nude mice after
subcutaneous implantation of cells expressing human epi-
dermal growth factor receptor 2 by affecting proliferation
in vivo [13]. They also demonstrated that carnosine inhi-
bits growth of cells from human malignant glioma and
identified carnosine as an inhibitor of anaerobic glycolysis
that is vital for the growth of gliomas [42]. A recent studyrevealed that carnosine inhibited tumor proliferation of
human colon cancer cells transplanted into athymic nude
mice, probably by elevating natural killer activity of splenic
cells [46]. Carnosine was also shown to inhibit KRAS-
mediated HCT116 proliferation [14], to inhibit metastasis
of SK-Hep-1 invasive hepatocarcinoma cells by inhibiting
expression and activity of matrix metalloproteinase 9 [47],
and to eliminate tumor cells from a mixture of normal
fibroblasts and HeLa cells [12].
As CA IX expression is predominantly associated with
tumors and is often a marker of poor prognosis, the
possible inhibition of its activity by carnosine deserves
further investigation because it could lead to anticancer
activity without blocking the expression of HIF-1α. The
fact that the binding of monoclonal antibodies to CA IX
is not inhibited at physiologic concentrations of car-
nosine can be perceived as an advantage as it enables the
use of immunotherapy with parallel blocking of CA IX
function by carnosine. The induction of CA IX protein
expression by carnosine could also be a positive side effect,
as it creates better conditions for immunotherapy through
increasing the number of target molecules.Conclusions
CA IX is often expressed in solid tumors and is considered
a marker of hypoxia and an indicator of poor prognosis.
Carnosine reduces the extracellular acidosis linked to cata-
lytic activity of CA IX in hypoxia and inhibits the growth
of spheroids and tumor xenografts. Our results suggest
that the interaction of carnosine with CA IX leads to con-
formational changes of the CA IX protein and impairs
formation of its metabolon, which in turn influences its
function. Thus, carnosine could be a promising anticancer
drug through its ability to attenuate the activity of CA IX.Additional files
Additional file 1: SiHa, HeLa, HT-29, MDCK CA IX and MDCK mock
cells were exposed to hypoxia for 48 hours in the presence of 20
mM carnosine. The columns in the graph represent endpoint values of
pH of carnosine treated cells and their respective untreated controls.
Carnosine caused a considerable alkalization of growth media in all
studied cell lines, except for MDCK mock cells where the effect of
carnosine was noticeably lower. Differences between control and
carnosine treated cells were evaluated by t-test (*p < 0.05, **p < 0.01).
Additional file 2: Western blot representing the expression level of
total CA IX protein and its phosphorylated form at threonine 443
in the intracellular tail in HeLa cells cultured in hypoxia with and
without 20 mM carnosine. Numbers underneath the protein bands
give the increase in the signal after carnosine treatment compared to
untreated cells. Carnosine did not cause increased phosphorylation of
T443 as the increase of levels of pT433 and total CA IX is comparable.
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